Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2007-09-18
2007-09-18
Lankford, Jr., Leon B. (Department: 1651)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C435S019000, C435S197000
Reexamination Certificate
active
10151481
ABSTRACT:
A method of treating an autoimmune disease comprising administering to the subject a treatment effective amount of a histone hyperacetylating agent, or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 4690918 (1987-09-01), Beppu et al.
patent: 5843885 (1998-12-01), Benedict et al.
patent: 5939455 (1999-08-01), Rephaeli
patent: 5993845 (1999-11-01), Geerts et al.
patent: 6071923 (2000-06-01), Nudelman et al.
patent: 6124495 (2000-09-01), Neiss et al.
patent: 6211440 (2001-04-01), Briggs et al.
patent: 6323334 (2001-11-01), Kingsbury et al.
patent: 6403555 (2002-06-01), Skov
patent: 6544957 (2003-04-01), Kern et al.
patent: 6667341 (2003-12-01), Lan-Hargest et al.
patent: 6855515 (2005-02-01), Rosen et al.
patent: 2003/0082666 (2004-07-01), Kammer et al.
patent: 2006/0030626 (2006-02-01), Kammer et al.
patent: 2 309 696 (1997-08-01), None
patent: 07206670 (1995-08-01), None
patent: WO93/19778 (1993-10-01), None
patent: WO97/11366 (1997-03-01), None
patent: WO 97/35990 (1997-10-01), None
patent: WO97/47307 (1997-12-01), None
patent: WO98/48825 (1998-11-01), None
patent: WO99/37150 (1999-07-01), None
patent: WO 00/08048 (2000-02-01), None
patent: WO00/21979 (2000-04-01), None
patent: WO 00/21979 (2000-04-01), None
patent: WO 00/23567 (2000-04-01), None
English Machine Translation of JP 07206670 from JAPIO website.
Taber's Medical Dictionary, 15th edition. 1981 (F.A. Davis Company: Philadelphia, PA) p. 982.
Kohge et al. “Promotion of antigen-specific antibody production in murine B cells by a moderate increase in histone acetylation” Biochem. Pharmacol. (1998) 56: 1359-1364.
Andrews et al.,Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents, International Journal of Parasitology, vol. 30, 2000, pp. 761-768.
Barnes,Anti-inflammatory actions of glucocorticoids: molecular mechanisms, Clinical Science, vol. 94, 1998, pp. 557-572.
Berden et al.,Role of Nucleosomes for Induction and Glomerular Binding of Autoantibodies in Lupus Nephritis, Current Opinion in Nephrology and Hypertension, vol. 8, No. 3, May 1999, pp. 299-306.
Brey et al.,Anti-Intercellular Adhesion Molecule-1(ICAM-1)antibody treatment prevents central and peripheral nervous system disease in autoimmune-prone mice, Lupus, vol. 6, 1997, pp. 645-651.
Brosch et al.,Abstract, Inhibition of maize histone deacetylases by HC toxin, the host-selective toxin of Cochliobolus carbonum, The Plant Cell, vol. 7, 1995, pp. 1941-1950.
Chiurazzi et al.,Synergistic Effect of Histone Hyperacetylation and DNA demethylation in the reactivation of the FMR1 gene, Human Molecular Genetics, vol. 8, No. 12, 1999, pp. 2317-2323.
Cress et al.,Histone Deacetylases, Transcriptional Control, and Cancer, Journal of Cellular Physiology, vol. 184, 2000, pp. 1-16.
Dangond et al.,Differential Display Cloning of a Novel Human Histone Deacetylase(HDAC3)cDNA from PHA-Activated Immune Cells, Biochemical and Biophysical Research Communications, vol. 242, 1998, pp. 648-652.
Darkin-Rattray et al.,Apicidin: A novel antiprotozoal agent that inhibits parasite histone deacetylase, Proc. Natl. Acad. Sci., USA, vol. 93, Nov. 1996, pp. 13143-13147.
Dayal et al.,The T Cell Enigma in Lupus, Arthritis & Rheumatism, vol. 39, No. 1, Jan. 1, 1996, pp. 23-33.
Desai-Mehta et al.,Hyperexpression of CD40 Ligand by B and T Cells in Human Lupus and Its Role in Pathogenic Autoantibody Production, J. Clin. Invest., vol. 97, No. 9, May 1996, pp. 2063-2073.
Finnin et al.,Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors, Nature, vol. 401, Sep. 9, 1999, pp. 188-193.
Glick et al.,PubMed Abstract, Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 Ligand expression in human neuroblastoma, Cancer Res, vol. 59, No. 17, Sep. 1, 1999, pp. 4392-4399.
Guan et al.,PubMed Abstract. Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer, Cancer Res, vol. 60, No. 3, Feb. 1, 2000, pp. 749-755.
Horwitz et al.,T Lymphocytes, Natural Killer Cells, Cytokines, and Immune Regulation, Dubois' Lupus Erythematosus, Wallace et al., eds., (Williams & Wilkins, Baltimore, 1997), pp. 155-194.
Huang et al.,Inhibition of IL-8 Gene Expression in CACO-2 Cells by Compounds Which Induce Histone Hyperacetylation, Cytokine, vol. 9, No. 1 Jan. 1997, pp. 27-36.
Huggins et al.,Antibodies from systemic lupus erythematosus(SLE)sera define differential release of autoantigens from cell lines undergoing apoptosis, Clin Exp Immunol, vol. 118, 1999, pp. 322-328.
Kijima et al.,Trapoxin, an Antitumor Cyclic Tetrapeptide, is an Irreversible Inhibitor of Mammalian Histone Deacetylase, The Journal of Biological Chemistry, vol. 268, No. 30, Oct. 25, 1993, pp. 22429-22435.
Kim et al.,Ikaros DNA-Binding Proteins Direct Formation of Chromatin Remodeling Complexes in Lymphocytes, Immunity, vol. 10, Mar. 1999, pp. 345-355.
Kim et al.,PubMed Abstract, Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase, Oncogene, vol. 18, No. 15, Apr. 15, 1999, pp. 2461-1470.
Kimberley,Characteristics of Immune Complexes and Principles of Immune Complex Diseases, Chapter 27, Arthritis and Allied Conditions: A Textbook of Rheumatology, W. J. Koopman, Ed., (williams & Wilkins, Baltimore, 1997), pp. 529-543.
Kohge et al.,PubMed Abstract, Promotion of antigen-specific antibody production in murine B cells by a moderate increase in histone acetylation, Biochem Pharmacol, vol. 56, No. 10, Nov. 15, 1998, pp. 1359-1364.
Koipally et al.,Repression by Ikaros and Aiolos is mediated through histone deacetylase complexes, The EMBO Journal, vol. 18, No. 11, 1999, pp. 3090-3100.
Kornberg et al.,Chromatin-modifying and -remodeling complexes, Current Opinion in Genetics & Development, vol. 9, 1999, pp. 148-151.
Koshy et al.,Increased Expression of CD40 Ligand on Systemic Lupus Erythematosus Lymphocytes. J. Clin. Invest, vol. 98, No. 3, Aug. 1996, pp. 826-837.
Kouzarides,Histone acetylases and deacetylases in cell proliferation, Current Opinion in Genetics & Development, vol. 9, 1999, pp. 40-48.
Kwon et al.,Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase, Proc. Natl. Acad. Sci. USA, vol. 95, Mar. 1998, pp. 3356-3361.
Lea et al.,Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deacetylase, Anticancer Res, vol. 15, No. 3, May-Jun. 1995, pp. 879-883.
Lea et al.,PubMed Abstract, Induction of histone acetylation and growth regulation in erythroleukemia cells by 4-phenylbutyrate and structural analogs, Anticancer Res, vol. 19, No. 3A, May-Jun. 1999, pp. 1971-1976.
McBain et al.,Apoptotic Death in Adenocarcinoma Cell Lines Induced by Butyrate and Other Histone Deacetylase Inhibitors, Biochemical Pharmacology, vol. 53, 1997, pp. 1357-1368.
Nakajima et al.,FR901228, a Potent Antitumor Antibiotic, is a Novel Histone Deacetylase Inhibitor, Experimental Cell Research, vol. 241, 1998, pp. 126-133.
Ohno et al.,Macrophage Inflammatory Protein-2: Chromosomal Regulation in Rate Small Intestinal Epithelial Cells, Proc. Natl. Acad. Sci. USA, vol. 94, Sep. 1997, pp. 10279-10284.
Qiu et al.,Histone Deacetylase Inhibitors Trigger a G2 Checkpoint in Normal Cells That is Defective in Tumor Cells, Molecular Biology of the Cell, vol. 11, Jun. 2000, pp. 2069-2083.
Richon et al.,A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases, Proc. Natl. Acad. Sci. USA, vol. 95, Mar. 1998, pp. 3003-3007.
Saito et al.,A synthetic Inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors, Proc. Natl. Acad. Sci. USA, vol. 96, apr. 1999, pp. 4592-4597.
Su et al.,Abstract, A Novel Histone Deacetylase Inhibitor Identified by High-Throughput Transcriptional Screening of a Compound Library, Cancer Research, vol. 60, Jun. 15, 2000, pp. 3137-3142.
Sun et al.,A General Requirement for the Sin3-Rpd3 Histone Deacetylase Complex in Regulating Silencing in Saccaromyces cerevisiae, Genetics
Kammer Gary M.
Mishra Nilamadhab
Hanley Susan
Lankford , Jr. Leon B.
Myers Bigel Sibley & Sajovec P.A.
Wake Forest University
LandOfFree
Method of treating autoimmune diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating autoimmune diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating autoimmune diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3737856